Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. S...
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT05212857
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Long-term Use of Mifepristone in the Treatment of Adenomyosis
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2021-12-09
- Target Recruit Count
- 140
- Registration Number
- NCT05151016
- Locations
- 🇨🇳
Women's Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2050
- Registration Number
- NCT05050084
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
Agonist Trigger With HCG Luteal Supplementation vs HCG Trigger With Progesterone Luteal Supplementation in Antagonist Controlled HyperstimulationCycle
- Conditions
- Interventions
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 100
- Registration Number
- NCT04846218
- Locations
- 🇪🇬
AinShams Maternity Hospital, Cairo, Egypt
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Damascus University
- Target Recruit Count
- 50
- Registration Number
- NCT04727684
- Locations
- 🇸🇾
Orient Hospital, Damascus, Syrian Arab Republic
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Damascus University
- Target Recruit Count
- 50
- Registration Number
- NCT04727671
- Locations
- 🇸🇾
Orient Hospital, Damascus, Syrian Arab Republic
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Damascus University
- Target Recruit Count
- 50
- Registration Number
- NCT04724343
- Locations
- 🇸🇾
Orient Hospital, Damascus, Syrian Arab Republic
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Damascus University
- Target Recruit Count
- 50
- Registration Number
- NCT04724486
- Locations
- 🇸🇾
Orient Hospital, Damascus, Syrian Arab Republic
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 43
- Registration Number
- NCT04659551
- Locations
- 🇮🇹
Arcispedale S. Anna, Cona, FE, Italy
🇮🇹Azienda Ospedaliera Universitaria di Parma, Parma, PR, Italy
🇮🇹Arcispedale S. Maria Nuova, Reggio Emilia, RE, Italy
Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2022-02-17
- Target Recruit Count
- 90
- Registration Number
- NCT04537078
- Locations
- 🇪🇬
Elshatby University Maternity Hospital, Alexandria, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.